

IN THE CLAIMS:

Please cancel claim 9 without prejudice or disclaimer.

Please enter the following amended claims:

1. (Amended) A substantially purified polypeptide comprising the amino acid sequence shown in SEQ ID NO. 3, 4, 8 or 9, or a homologue thereof having at least 95% sequence identity over the full length of the amino acid sequence and having the same function.
2. (Amended) A polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NO. 3, 4, 8 or 9.
3. (Amended) A cDNA encoding the polypeptide according to claim 1, or a cDNA encoding a homologue of a polypeptide according to claim 1 having at least 95% sequence identity over the full-length of the nucleotide sequence shown in SEQ ID NO: 1, 5, 6 or 10.
4. (Amended) A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NO. 1, 5, 6 or 10.
5. (Amended) A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NO. 2 or 7.
6. (Amended) A replication or expression vector comprising the cDNA according to any one of claims 3 to 5.
8. (Amended) A method for producing a polypeptide of SEQ ID NO: 3, 4, 8 or 9, or a homologue thereof having at least 95% sequence identity over the full length of the amino acid sequence and having the same function, comprising culturing a host cell of claim 7 under a condition effective to express the polypeptide, and recovering the polypeptide so expressed.

10. (Amended) A pharmaceutical composition comprising the polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent or carrier, or both.

11. (Amended) A pharmaceutical composition for the treatment of abnormal growth of a smooth muscle cell, said composition comprising a polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent or carrier, or both.

12. (Amended) A pharmaceutical composition for the treatment of arteriosclerosis, restenosis after PTCA or myosarcoma, said composition comprising a polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent or carrier, or both.

13. (Amended) A method for screening for an antagonist or agonist of a polypeptide according to claim 1 or 2, said method comprising preparing a first and second culture of a cell line, culturing said first cell line in the presence of one or more of said polypeptides, culturing said second cell line in the presence of one or more of said polypeptides and a test compound, and comparing the proliferation of the two cultures, thereby screening for an antagonist or agonist of a polypeptide according to claim 1 or 2.

Please add the following new claim:

14. A cDNA encoding a polypeptide according to claim 2.